Discovery of 5-(N-hydroxycarbamimidoyl) benzofuran derivatives as novel indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors. (15th May 2021)

• Record Type: Journal Article
• Authors: Jung, Juyoung; Yoon, Hongchul; Sohn, Te-ik; Jang, Kyusic; Yoo, Yeongran; Jeong, Ilji; Shin, Jae Eui; Lee, Jin Hee; Ann, Jihyae; Lee, Jeewoo
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 40(2021)
• Publication Date: 2021-05-15
• Subjects: Indoleamine 2 -- 3-Dioxygenase 1 -- Kynurenine Pathway -- Immunotherapy; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2021.127963
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: Human indoleamine 2, 3-dioxygenase 1 ( h IDO1) and tryptophan dioxygenase ( h TDO) are rate-limiting enzymes in the kynurenine pathway (KP) of l - tryptophan ( l - Trp) metabolism and are becoming key drug targets in the combination therapy of checkpoint inhibitors in immunoncology. To discover a selective and potent IDO1 inhibitor, a structure–activity relationship (SAR) study of N -hydroxybenzofuran-5-carboximidamide as a novel scaffold was investigated in a systematic manner. Among the synthesized compounds, the N -3-bromophenyl derivative 19 showed the most potent inhibition, with an IC50 value of 0.44 μM for the enzyme and 1.1 μM in HeLa cells. The molecular modeling of 19 with the X-ray crystal structure of IDO1 indicated that dipole-ionic interactions with heme iron, halogen bonding with Cys129 and the two hydrophobic interactions were important for the high potency of 19 .